Moody Lynn & Lieberson’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $76.7M | Sell |
83,422
-198
| -0.2% | -$201K | 4.31% | 4 |
|
|
2025
Q4 | $89.9M | Buy |
83,620
+2,657
| +3% | +$2.54M | 4.76% | 5 |
|
|
2025
Q3 | $61.8M | Sell |
80,963
-853
| -1% | -$635K | 3.33% | 8 |
|
|
2025
Q2 | $63.8M | Sell |
81,816
-2,224
| -3% | -$1.73M | 3.68% | 5 |
|
|
2025
Q1 | $69.4M | Sell |
84,040
-1,336
| -2% | -$1.11M | 4.45% | 4 |
|
|
2024
Q4 | $65.9M | Sell |
85,376
-4,209
| -5% | -$3.49M | 4.04% | 6 |
|
|
2024
Q3 | $79.4M | Sell |
89,585
-1,840
| -2% | -$1.65M | 4.89% | 4 |
|
|
2024
Q2 | $82.8M | Buy |
91,425
+247
| +0.3% | +$198K | 5.42% | 4 |
|
|
2024
Q1 | $70.9M | Buy |
91,178
+298
| +0.3% | +$212K | 4.77% | 4 |
|
|
2023
Q4 | $53M | Buy |
90,880
+171
| +0.2% | +$99.8K | 4.03% | 5 |
|
|
2023
Q3 | $48.7M | Sell |
90,709
-7,807
| -8% | -$4.02M | 4.18% | 4 |
|
|
2023
Q2 | $46.2M | Buy |
98,516
+166
| +0.2% | +$69.6K | 3.73% | 5 |
|
|
2023
Q1 | $33.8M | Sell |
98,350
-3,882
| -4% | -$1.31M | 3.04% | 5 |
|
|
2022
Q4 | $37.4M | Buy |
102,232
+2,142
| +2% | +$759K | 3.42% | 3 |
|
|
2022
Q3 | $32.4M | Sell |
100,090
-5,826
| -6% | -$1.85M | 3.12% | 4 |
|
|
2022
Q2 | $34.3M | Sell |
105,916
-9,490
| -8% | -$2.85M | 3.09% | 5 |
|
|
2022
Q1 | $33M | Sell |
115,406
-5,070
| -4% | -$1.3M | 2.42% | 9 |
|
|
2021
Q4 | $33.3M | Sell |
120,476
-203
| -0.2% | -$51.5K | 2.23% | 12 |
|
|
2021
Q3 | $27.9M | Sell |
120,679
-701
| -0.6% | -$173K | 2.09% | 13 |
|
|
2021
Q2 | $27.9M | Buy |
121,380
+24,071
| +25% | +$4.84M | 2.1% | 12 |
|
|
2021
Q1 | $18.2M | Sell |
97,309
-920
| -0.9% | -$180K | 1.51% | 22 |
|
|
2020
Q4 | $16.6M | Buy |
98,229
+13,739
| +16% | +$2.05M | 1.42% | 27 |
|
|
2020
Q3 | $12.5M | Sell |
84,490
-7,742
| -8% | -$1.2M | 1.24% | 30 |
|
|
2020
Q2 | $15.1M | Sell |
92,232
-21,041
| -19% | -$3.23M | 1.64% | 18 |
|
|
2020
Q1 | $15.7K | Buy |
+113,273
| New | +$15.6M | 2.16% | 11 |
|
|
2019
Q1 | – | Sell |
-44,291
| Closed | -$5.13M | – | 197 |
|
|
2018
Q4 | $5.13M | Buy |
+44,291
| New | +$4.95M | 0.69% | 45 |
|
|
2018
Q1 | – | Sell |
-11,537
| Closed | -$993K | – | 213 |
|
|
2017
Q4 | $993K | Sell |
11,537
-152
| -1% | -$12.9K | 0.11% | 109 |
|
|
2017
Q3 | $1M | Sell |
11,689
-20
| -0.2% | -$1.64K | 0.12% | 106 |
|
|
2017
Q2 | $964K | Sell |
11,709
-2,104
| -15% | -$172K | 0.13% | 103 |
|
|
2017
Q1 | $1.16M | Sell |
13,813
-171
| -1% | -$13.7K | 0.16% | 84 |
|
|
2016
Q4 | $1.03M | Sell |
13,984
-5,233
| -27% | -$390K | 0.15% | 89 |
|
|
2016
Q3 | $1.54M | Sell |
19,217
-32
| -0.2% | -$2.56K | 0.26% | 78 |
|
|
2016
Q2 | $1.52M | Buy |
19,249
+2,079
| +12% | +$157K | 0.27% | 66 |
|
|
2016
Q1 | $1.24M | Sell |
17,170
-5,294
| -24% | -$401K | 0.19% | 83 |
|
|
2015
Q4 | $1.89M | Sell |
22,464
-7,320
| -25% | -$607K | 0.3% | 80 |
|
|
2015
Q3 | $2.49M | Sell |
29,784
-3,899
| -12% | -$329K | 0.48% | 60 |
|
|
2015
Q2 | $2.81M | Sell |
33,683
-385
| -1% | -$29.3K | 0.45% | 66 |
|
|
2015
Q1 | $2.48M | Sell |
34,068
-5,001
| -13% | -$356K | 0.39% | 67 |
|
|
2014
Q4 | $2.69M | Sell |
39,069
-584
| -1% | -$39.4K | 0.38% | 70 |
|
|
2014
Q3 | $2.57M | Sell |
39,653
-541
| -1% | -$34.3K | 0.38% | 72 |
|
|
2014
Q2 | $2.5M | Sell |
40,194
-84
| -0.2% | -$5.01K | 0.34% | 79 |
|
|
2014
Q1 | $2.37M | Buy |
40,278
+3,729
| +10% | +$208K | 0.34% | 83 |
|
|
2013
Q4 | $1.86M | Sell |
36,549
-2,653
| -7% | -$133K | 0.25% | 94 |
|
|
2013
Q3 | $1.97M | Sell |
39,202
-47
| -0.1% | -$2.46K | 0.31% | 89 |
|
|
2013
Q2 | $1.93M | Buy |
+39,249
| New | +$2.14M | 0.34% | 77 |
|
Other funds holding LLY
VCM
VPM
Moody Lynn & Lieberson's LLY Position: Q1 2026 in Review
Moody Lynn & Lieberson reduced its Eli Lilly (LLY) stake by 0.24% in Q1 2026, selling an estimated $201K and leaving 83,422 shares worth $76.7M. The position accounts for 4.31% of the portfolio, ranked #4.
Moody Lynn & Lieberson first reported a position in LLY in Q2 2013 and has held it in 45 quarters since. The position peaked at $89.9M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Moody Lynn & Lieberson held 83,422 shares of Eli Lilly worth $76.7M as of Q1 2026.
- Moody Lynn & Lieberson sold 198 Eli Lilly shares in Q1 2026, an estimated $201K.
- Eli Lilly made up 4.31% of Moody Lynn & Lieberson's portfolio in Q1 2026, its #4 holding.
- Moody Lynn & Lieberson first reported a position in Eli Lilly in Q2 2013 and has held it in 45 quarters since.
- Moody Lynn & Lieberson's Eli Lilly position peaked at $89.9M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Moody Lynn & Lieberson's 13F filing for Q1 2026, filed 13 Apr 2026.